# AI Readiness Roadmap - Healthcare Industry Supplement

**Version:** 1.0
**Date:** ___________________________
**Organization:** ___________________________
**Industry:** Healthcare & Life Sciences

---

## How to Use This Supplement

This healthcare-specific supplement provides industry-tailored content for the base AI Readiness Roadmap. Use it to customize:
- Section 2-3: Executive Summary (ROI opportunities)
- Section 4-6: Where AI Creates ROI (healthcare use cases)
- Section 13-14: Vendor Recommendations (healthcare vendors)
- Section 15: Risk Assessment (healthcare-specific risks and compliance)

---

## Healthcare AI ROI Opportunities

### Clinical Operations - ROI Scoring

| Opportunity | Current State | AI-Enabled State | ROI Range | Confidence | Priority |
|-------------|---------------|------------------|-----------|------------|----------|
| Clinical Documentation (NLP) | _____ hrs/physician/day | _____ hrs saved | 180-320% | High / Medium / Low | ___ |
| Medical Imaging Analysis | _____ images/day | _____ AI-assisted | 150-280% | High / Medium / Low | ___ |
| Patient Triage & Routing | ___% accuracy | ___% accuracy | 120-200% | High / Medium / Low | ___ |
| Revenue Cycle Management | ___% denial rate | ___% reduction | 200-350% | High / Medium / Low | ___ |
| Prior Authorization | _____ days avg | _____ days AI-enabled | 150-250% | High / Medium / Low | ___ |
| Medical Coding (ICD-10/CPT) | ___% accuracy | ___% accuracy | 180-300% | High / Medium / Low | ___ |
| Drug Interaction Checking | _____ alerts/day | ___% reduction (clinically relevant) | 100-180% | High / Medium / Low | ___ |
| Patient No-Show Prediction | ___% no-show rate | ___% reduction | 80-150% | High / Medium / Low | ___ |

### Revenue Impact Calculation - Healthcare

| Opportunity | Annual Revenue/Savings | Implementation Cost | Net 3-Year Value | Score |
|-------------|----------------------|---------------------|------------------|-------|
| Clinical Documentation AI | $____________ | $____________ | $____________ | ___/100 |
| Radiology AI Assist | $____________ | $____________ | $____________ | ___/100 |
| Revenue Cycle AI | $____________ | $____________ | $____________ | ___/100 |
| Predictive Patient Flow | $____________ | $____________ | $____________ | ___/100 |
| Population Health AI | $____________ | $____________ | $____________ | ___/100 |

---

## Healthcare-Specific Cost Reduction

### Clinical & Administrative Automation

| Process Area | Current Cost | Automation Potential | Savings Range | Complexity | Priority |
|--------------|--------------|---------------------|---------------|------------|----------|
| Clinical Documentation | $_______ / year | ____% | 40-60% | High | ___ |
| Medical Coding | $_______ / year | ____% | 35-55% | Medium | ___ |
| Prior Authorization | $_______ / year | ____% | 50-70% | Medium | ___ |
| Claims Processing | $_______ / year | ____% | 40-65% | Medium | ___ |
| Scheduling Optimization | $_______ / year | ____% | 30-50% | Low | ___ |
| Patient Intake | $_______ / year | ____% | 35-55% | Low | ___ |
| Quality Reporting | $_______ / year | ____% | 45-65% | Medium | ___ |
| Referral Management | $_______ / year | ____% | 30-50% | Low | ___ |

---

## Healthcare Risk Mitigation Value

### Clinical & Compliance Risk Reduction

| Risk Category | Current Exposure | AI Mitigation | Value Protected | Confidence |
|---------------|------------------|---------------|-----------------|------------|
| Medical Errors | $_______ / year | ___% reduction | $____________ | High / Medium / Low |
| HIPAA Violations | $_______ / year | ___% reduction | $____________ | High / Medium / Low |
| Readmission Penalties | $_______ / year | ___% reduction | $____________ | High / Medium / Low |
| Clinical Liability | $_______ / year | ___% reduction | $____________ | High / Medium / Low |
| Coding Compliance | $_______ / year | ___% reduction | $____________ | High / Medium / Low |
| **Total Risk Mitigation Value** | **$_______** | | **$____________** | |

---

## Healthcare Build vs. Buy Considerations

### Healthcare-Specific BUILD Indicators

| Factor | Score (1-5) | Healthcare Considerations |
|--------|-------------|--------------------------|
| Clinical differentiation | ___/5 | Does AI create unique clinical capabilities? |
| Proprietary clinical data | ___/5 | EHR data, outcomes data, clinical notes |
| Clinical domain expertise | ___/5 | In-house clinical informatics capabilities |
| Integration with clinical workflows | ___/5 | Deep EHR integration requirements |
| Regulatory approval pathway | ___/5 | FDA SaMD classification considerations |

### Healthcare-Specific BUY Indicators

| Factor | Score (1-5) | Healthcare Considerations |
|--------|-------------|--------------------------|
| FDA-cleared solutions available | ___/5 | Pre-approved clinical AI solutions |
| HIPAA-compliant vendors | ___/5 | BAA-ready enterprise vendors |
| EHR vendor AI capabilities | ___/5 | Epic, Cerner, Meditech native AI |
| Clinical validation studies | ___/5 | Published clinical evidence |
| Implementation track record | ___/5 | Health system reference customers |

---

## Healthcare Vendor Landscape

### Clinical AI Platforms

| Vendor | Product | Clinical Focus | FDA Status | EHR Integration | Score |
|--------|---------|----------------|------------|-----------------|-------|
| Nuance/MSFT | DAX | Clinical documentation | N/A | Epic, Cerner | ___/5 |
| Google Health | Med-PaLM | Clinical Q&A | Research | Limited | ___/5 |
| Epic | Cognitive Computing | Multi-purpose | In-progress | Native | ___/5 |
| Aidoc | aiDoc | Radiology triage | FDA cleared | PACS | ___/5 |
| Viz.ai | Viz Platform | Stroke detection | FDA cleared | PACS | ___/5 |
| PathAI | PathAI | Pathology | FDA cleared | LIS | ___/5 |

### Revenue Cycle AI

| Vendor | Product | Focus Area | Claim Volume | Integration | Score |
|--------|---------|------------|--------------|-------------|-------|
| Olive AI | Olive | RPA + AI | High volume | Multi-EHR | ___/5 |
| Waystar | Waystar | Claims management | High volume | Multi-EHR | ___/5 |
| Change Healthcare | AI Suite | Payer-provider | Enterprise | Extensive | ___/5 |
| AKASA | AKASA | Revenue cycle | Mid-large | Epic, Cerner | ___/5 |

---

## Healthcare Compliance Requirements

### Regulatory Framework

| Regulation | Applicability | Requirements | AI Impact |
|------------|---------------|--------------|-----------|
| **HIPAA** | All PHI handling | BAA required, minimum necessary, encryption | Data training restrictions, de-identification |
| **FDA SaMD** | Clinical decision support | 510(k) or De Novo if diagnosis/treatment | Regulatory approval pathway for clinical AI |
| **HITECH** | EHR incentives | Meaningful use, security requirements | Data quality for AI training |
| **State Privacy** | State-specific | Varying consent requirements | State-by-state compliance |
| **CMS Conditions** | Medicare participation | Care quality standards | AI must not compromise care |

### FDA Software as Medical Device (SaMD) Classification

| Risk Level | Class | Examples | Pathway | Timeline |
|------------|-------|----------|---------|----------|
| Low | Class I | Wellness apps, general health | Exempt or 510(k) | 3-6 months |
| Medium | Class II | Diagnostic decision support | 510(k) | 6-12 months |
| High | Class III | Life-sustaining, diagnosis | PMA | 18-36 months |

### HIPAA Business Associate Agreement (BAA) Checklist

| Requirement | Vendor A | Vendor B | Vendor C |
|-------------|----------|----------|----------|
| BAA execution | Yes / No | Yes / No | Yes / No |
| PHI handling documented | Yes / No | Yes / No | Yes / No |
| De-identification protocols | Yes / No | Yes / No | Yes / No |
| Breach notification (<60 days) | Yes / No | Yes / No | Yes / No |
| Minimum necessary principle | Yes / No | Yes / No | Yes / No |
| Security safeguards documented | Yes / No | Yes / No | Yes / No |
| Subcontractor flow-down | Yes / No | Yes / No | Yes / No |
| Return/destruction of PHI | Yes / No | Yes / No | Yes / No |

---

## Healthcare-Specific Risk Assessment

### Clinical Safety Risks

| Risk | Likelihood | Impact | Mitigation | Status |
|------|------------|--------|------------|--------|
| AI diagnostic error | ___/5 | Critical | Human-in-the-loop review | Not Started / In Progress / Mitigated |
| Treatment recommendation harm | ___/5 | Critical | Clinical validation, override capability | Not Started / In Progress / Mitigated |
| Alert fatigue from AI | ___/5 | High | Threshold tuning, clinician feedback | Not Started / In Progress / Mitigated |
| Bias in patient populations | ___/5 | High | Diverse training data, ongoing monitoring | Not Started / In Progress / Mitigated |
| Medication dosing errors | ___/5 | Critical | Integration testing, pharmacist review | Not Started / In Progress / Mitigated |

### Data & Privacy Risks

| Risk | Likelihood | Impact | Mitigation | Status |
|------|------------|--------|------------|--------|
| PHI exposure in AI training | ___/5 | Critical | De-identification, synthetic data | Not Started / In Progress / Mitigated |
| HIPAA breach from AI vendor | ___/5 | Critical | BAA, security assessments | Not Started / In Progress / Mitigated |
| Patient consent gaps | ___/5 | High | Consent workflows, opt-out mechanisms | Not Started / In Progress / Mitigated |
| Data portability limitations | ___/5 | Medium | Vendor contracts, data access provisions | Not Started / In Progress / Mitigated |

### Operational Risks

| Risk | Likelihood | Impact | Mitigation | Status |
|------|------------|--------|------------|--------|
| EHR integration failures | ___/5 | High | Testing, fallback procedures | Not Started / In Progress / Mitigated |
| Clinical workflow disruption | ___/5 | High | Change management, training | Not Started / In Progress / Mitigated |
| Clinician adoption resistance | ___/5 | Medium | Pilot approach, clinical champions | Not Started / In Progress / Mitigated |
| AI model drift | ___/5 | High | Continuous monitoring, retraining | Not Started / In Progress / Mitigated |

---

## Healthcare Governance Additions

### Clinical AI Governance Structure

| Role | Responsibilities | Recommended Assignment |
|------|------------------|----------------------|
| Chief Medical Officer | Clinical safety oversight, final approval | CMO or designee |
| Chief Medical Informatics Officer | Clinical AI strategy, EHR integration | CMIO |
| Clinical AI Safety Officer | Adverse event monitoring, clinical validation | New or assigned role |
| IRB Representative | Research oversight, patient protection | IRB chair or designee |
| Quality Officer | Quality metrics, CMS compliance | Chief Quality Officer |

### Clinical AI Review Board Charter

| Element | Requirement |
|---------|-------------|
| **Purpose** | Review and approve clinical AI use cases for patient safety |
| **Membership** | CMO, CMIO, Quality, Risk, Legal, Clinical champions |
| **Frequency** | Monthly or as needed for new AI deployments |
| **Authority** | Go/no-go decision for clinical AI deployment |
| **Documentation** | Meeting minutes, approval records, adverse event log |

### Patient Safety Monitoring

| Metric | Threshold | Frequency | Responsible |
|--------|-----------|-----------|-------------|
| AI-related adverse events | 0 critical | Continuous | Clinical AI Safety Officer |
| Diagnostic accuracy | > ___% | Weekly | CMIO |
| False positive rate | < ___% | Weekly | Clinical team |
| Clinician override rate | < ___% | Weekly | Quality |
| Patient complaints (AI-related) | < ___/month | Monthly | Patient relations |

---

## Healthcare 90-Day Roadmap Additions

### Week 1-2: Clinical Requirements

| Activity | Owner | Deliverable |
|----------|-------|-------------|
| Clinical use case validation with CMO | _____________________ | Clinical approval |
| IRB determination (if research) | _____________________ | IRB exemption/approval |
| FDA SaMD classification assessment | _____________________ | Regulatory pathway |
| Clinical champion identification | _____________________ | Champion roster |

### Week 3-4: Healthcare Data Assessment

| Activity | Owner | Deliverable |
|----------|-------|-------------|
| PHI inventory for AI training | _____________________ | Data inventory |
| De-identification strategy | _____________________ | De-ID protocol |
| EHR data extraction capabilities | _____________________ | Data pipeline design |
| HIPAA security review | _____________________ | Security assessment |

### Week 5-8: Clinical Pilot Design

| Activity | Owner | Deliverable |
|----------|-------|-------------|
| Clinical workflow mapping | _____________________ | Workflow documentation |
| EHR integration design | _____________________ | Integration spec |
| Clinical validation protocol | _____________________ | Validation plan |
| Patient consent approach | _____________________ | Consent workflow |

---

## Healthcare Success Metrics

### Clinical Quality Metrics

| Metric | Baseline | Target | Current | Source |
|--------|----------|--------|---------|--------|
| Diagnostic accuracy | ____% | ____% | ____% | Quality dashboard |
| Documentation completeness | ____% | ____% | ____% | EHR audit |
| Time to diagnosis | ____ hrs | ____ hrs | ____ hrs | EHR analytics |
| Patient wait time | ____ min | ____ min | ____ min | Operations |
| Readmission rate | ____% | ____% | ____% | Quality metrics |

### Operational Metrics

| Metric | Baseline | Target | Current | Source |
|--------|----------|--------|---------|--------|
| Documentation time/encounter | ____ min | ____ min | ____ min | Time studies |
| Prior auth turnaround | ____ days | ____ days | ____ days | RCM system |
| Clean claim rate | ____% | ____% | ____% | Billing system |
| Staff satisfaction (AI tools) | ___/5 | ___/5 | ___/5 | Survey |

---

## Document Information

**GenAI Maturity Portal:** https://genaimaturity.net
**Assessment Tools:** https://genaimaturity.net/assessment
**Implementation Resources:** https://genaimaturity.net/implementation

---

_This healthcare supplement provides industry-specific customization for the AI Readiness Roadmap. Use in conjunction with the base strategic document._

**Document Version:** 1.0
**Last Updated:** ___________________________